ISO-1, a MIF inhibitor, reduces SIX1-mediated cell proliferation and the expression levels of α-SMA and Col1a1, providing a potential pathway for IPF therapy [58]. This evidence concerns the gene SIX1 and idiopathic pulmonary fibrosis.